Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas.
Type | Public | |
Founded | 2000 | |
HQ | Lexington, MA, US | Map |
Website | curis.com | |
Employee Ratings | ||
Overall Culture | B- | More |
USD | |
---|---|
Revenue (Q1, 2022) | 2.1m |
Net income (Q1, 2022) | (16.5m) |
EBIT (Q1, 2022) | (15.1m) |
Market capitalization (29-Jul-2022) | 90.3m |
Closing stock price (29-Jul-2022) | 1.0 |
Cash (31-Mar-2022) | 18.5m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 392.9k | 147.1k | 10.4m | 4.4m | 577.8k | 871.4k | 5.4m | 7.2m | 1.3m | 4.8m | 1.8m | 1.7m | 2.1m | 2.0m | 1.7m | 1.7m | 1.8m | 2.1m | 2.1m | 2.4m | 2.5m | 2.4m | 2.8m | 1.8m | 2.1m | 2.9m | 2.7m | 2.4m | 2.2m | 2.3m | 3.1m | 2.1m |
General and administrative expense | 1.9m | 1.9m | 2.8m | 2.3m | 2.5m | 2.6m | 2.9m | 2.8m | 2.8m | 2.9m | 2.7m | 3.5m | 3.4m | 2.8m | 3.6m | 3.4m | 4.7m | 3.5m | 3.8m | 3.4m | 4.0m | 3.6m | 4.1m | 3.1m | 2.5m | 2.9m | 3.6m | 4.1m | 5.7m | |||
R&D expense | 3.1m | 3.0m | 5.2m | 4.5m | 3.0m | 2.6m | 3.2m | 121.9k | 3.1m | 3.3m | 3.7m | 4.7m | 5.9m | 4.0m | 6.8m | 8.8m | 6.8m | 13.5m | 11.3m | 13.4m | 8.3m | 6.5m | 5.0m | 4.1m | 5.6m | 5.1m | 7.5m | 6.8m | 11.4m | |||
Operating expense total | 5.0m | 5.0m | 8.0m | 6.8m | 5.5m | 5.2m | 6.1m | 7.1m | 6.0m | 6.3m | 6.4m | 8.2m | 9.3m | 6.9m | 10.4m | 12.3m | 11.5m | 17.1m | 15.1m | 16.8m | 12.2m | 10.1m | 9.1m | 7.2m | 8.1m | 8.0m | 11.1m | 10.9m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 6.8m | 11.9m | 14.7m | 12.1m | 7.8m | 9.7m | 9.7m | 13.8m | 7.9m | 10.2m | 7.9m | 23.5m | 31.5m | 28.7m | 14.7m | 8.6m | 20.7m | 42.4m | 26.7m | 49.8m | 24.7m | 30.5m | 25.6m | 42.8m | 27.2m | 21.4m | 12.5m | 23.6m | 111.0m | 75.0m | 53.0m | 18.5m |
Accounts Receivable | 99.5k | 137.3k | 339.8k | 318.3k | 548.4k | 764.4k | 863.2k | 1.2m | 1.4m | 4.8m | 1.8m | 1.8m | 2.1m | 2.3m | 1.7m | 1.9m | 1.9m | 2.2m | 2.2m | 2.5m | 2.5m | 2.5m | 2.9m | 1.8m | 2.1m | 2.9m | 2.5m | 2.5m | 2.2m | 2.4m | 3.0m | 2.1m |
Prepaid Expenses | 475.1k | 676.0k | 351.3k | 397.1k | 498.1k | 398.5k | 413.5k | 505.1k | 501.7k | 363.4k | 655.8k | 828.3k | 777.4k | 818.2k | 928.4k | 975.0k | 1.4m | 1.2m | 958.0k | 1.2m | 909.0k | 776.0k | 1.1m | 681.0k | 819.0k | 1.6m | 1.3m | 1.0m | 3.3m | 1.6m | 3.1m | 3.4m |
Current Assets | 33.3m | 29.2m | 45.7m | 45.4m | 42.2m | 51.7m | 58.4m | 64.9m | 59.6m | 61.0m | 57.1m | 102.6m | 102.1m | 96.6m | 75.8m | 64.5m | 56.6m | 64.4m | 54.4m | 73.0m | 51.9m | 43.7m | 34.8m | 45.4m | 38.4m | 32.7m | 16.5m | 27.3m | 161.9m | 156.5m | 135.0m | 126.1m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (9.9m) | (16.4m) | (12.3m) | (18.7m) | (59.0m) | (60.4m) | (53.3m) | (32.1m) | (45.4m) | ||
Depreciation and Amortization | 107.4k | 126.5k | 141.5k | 155.1k | 160.8k | 193.0k | 125.0k | 144.0k | |||
Accounts Payable | 416.2k | 20.3k | 181.8k | 360.9k | 1.8m | 2.3m | (376.0k) | (1.9m) | 60.0k | 1.0m | 5.0m |
Cash From Operating Activities | (4.6m) | (15.2m) | (9.5m) | (16.8m) | (29.9m) | (35.8m) | (48.4m) | (30.1m) | (26.2m) | (25.7m) | (37.6m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.2 x |
Curis has 271 Twitter Followers. The number of followers has increased 1.8% month over month and increased 5.6% quarter over quarter
79
Tweets
54
Following
271
Followers
1
Tweets last 30 days
5
Avg. likes per Tweet
100%
Tweets with engagement
B-
78/100
A
83/100
B
81/100
When was Curis founded?
Curis was founded in 2000.
Who are Curis key executives?
Curis's key executives are Rachel Blasbalg, Kenneth I. Kaitin and John Hohneker.
How many employees does Curis have?
Curis has 31 employees.
What is Curis revenue?
Latest Curis annual revenue is $10.6 m.
What is Curis revenue per employee?
Latest Curis revenue per employee is $343.5 k.
Who are Curis competitors?
Competitors of Curis include Intrepida Bio, Ionova Life Science and Verseau Therapeutics.
Where is Curis headquarters?
Curis headquarters is located at 4 Maguire Rd, Lexington.
Where are Curis offices?
Curis has an office in Lexington.
How many offices does Curis have?
Curis has 2 offices.
Receive alerts for 300+ data fields across thousands of companies